Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T52522
|
||||
Former ID |
TTDS00037
|
||||
Target Name |
Beta-2 adrenergic receptor
|
||||
Gene Name |
ADRB2
|
||||
Synonyms |
Beta-2 adrenoceptor; Beta-2 adrenoreceptor; ADRB2
|
||||
Target Type |
Successful
|
||||
Disease | Asthma; Chronic obstructive pulmonary disease [ICD9:490-492, 494-496; ICD10: J45, J40-J44, J47] | ||||
Aging skin; Exacerbations of acute asthma [ICD9:493; ICD10: L00-L99, J45] | |||||
Asthma [ICD10: J45] | |||||
Acute asthma [ICD9: 493; ICD10: J45] | |||||
Asthma; Chronic obstructive pulmonary disease [ICD9: 490-492, 493, 494-496; ICD10: J40-J44, J47, J45] | |||||
Bradycardia; Heart block [ICD9: 116.0, 426.9; ICD10: B40, I44-I45] | |||||
Bronchodilator [ICD9: 493; ICD10: J45] | |||||
Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10: J40-J44, J47] | |||||
Chronic breathing disorders [ICD9: 490-496; ICD10: J44-J47] | |||||
Chronic obstructive pulmonary disease; Asthma [ICD9: 490-492, 493, 494-496; ICD10: J40-J44, J47, J45] | |||||
Cachexia [ICD9: 799.4; ICD10: R64] | |||||
Hypertension [ICD9: 401; ICD10: I10-I16] | |||||
Neurogenic bladder dysfunction [ICD10: N31.9] | |||||
Obesity [ICD9: 278; ICD10: E66] | |||||
Premature ejaculation [ICD9: 302.75; ICD10: F52.4] | |||||
Premature labour [ICD9: 644, 765; ICD10: O60.1, P07.3] | |||||
Skin infections [ICD9: 680-709; ICD10: L00-L99] | |||||
Unspecified [ICD code not available] | |||||
Function |
Beta-adrenergic receptors mediate the catecholamine- induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
|
||||
BioChemical Class |
GPCR rhodopsin
|
||||
Target Validation |
T52522
|
||||
UniProt ID | |||||
Sequence |
MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAK
FERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTAS IETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQE AINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRF HVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQD NLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNT GEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL |
||||
Drugs and Mode of Action | |||||
Drug(s) | Arformoterol | Drug Info | Approved | Chronic obstructive pulmonary disease | [536223], [542501] |
Bambuterol | Drug Info | Approved | Asthma | [536361], [541721] | |
Clenbuterol | Drug Info | Approved | Chronic breathing disorders | [550744] | |
Fenoterol | Drug Info | Approved | Asthma | [536567], [540946] | |
Formoterol | Drug Info | Approved | Asthma | [536535], [540403] | |
GW642444 | Drug Info | Approved | Asthma | [532150], [532651] | |
Indacaterol | Drug Info | Approved | Chronic obstructive pulmonary disease | [531783], [542479] | |
Isoetharine | Drug Info | Approved | Asthma | [538363], [542219] | |
Isoproterenol | Drug Info | Approved | Bradycardia; Heart block | [538350] | |
Levalbuterol | Drug Info | Approved | Asthma | [545941], [551871] | |
Metaproterenol Sulfate | Drug Info | Approved | Asthma | [551871] | |
Olodaterol | Drug Info | Approved | Chronic obstructive pulmonary disease | [533123], [542545] | |
Orciprenaline | Drug Info | Approved | Asthma | [542268], [550662] | |
Pirbuterol | Drug Info | Approved | Asthma | [536361], [542292] | |
Procaterol | Drug Info | Approved | Asthma | [540402], [550747] | |
Ritodrine | Drug Info | Approved | Premature labour | [538236], [542314] | |
Salbutamol | Drug Info | Approved | Acute asthma | [536500], [540951] | |
Salmeterol | Drug Info | Approved | Chronic obstructive pulmonary disease | [536361], [540957] | |
Terbutaline | Drug Info | Approved | Asthma | [538303], [540968] | |
Vilanterol | Drug Info | Approved | Asthma; Chronic obstructive pulmonary disease | [524423], [542374], [551871] | |
GSK642444 | Drug Info | Phase 3 | Chronic obstructive pulmonary disease | [537130] | |
PT005 | Drug Info | Phase 3 | Chronic obstructive pulmonary disease | [525067] | |
QVA-149 | Drug Info | Phase 3 | Chronic obstructive pulmonary disease | [551966] | |
APD-209 | Drug Info | Phase 2 | Cachexia | [524508] | |
AZD-2115 | Drug Info | Phase 2 | Chronic obstructive pulmonary disease | [524708] | |
AZD-3199 | Drug Info | Phase 2 | Asthma | [522407] | |
BUCINDOLOL | Drug Info | Phase 2 | Hypertension | [524493] | |
Carmoterol | Drug Info | Phase 2 | Chronic obstructive pulmonary disease | [537130], [542572] | |
GSK961081 | Drug Info | Phase 2 | Chronic obstructive pulmonary disease | [548296] | |
LAS 100977 | Drug Info | Phase 2 | Asthma; Chronic obstructive pulmonary disease | [548577] | |
MN-221 | Drug Info | Phase 2 | Aging skin; Exacerbations of acute asthma | [522325] | |
R-salbutamol sulphate | Drug Info | Phase 2 | Skin infections | [522239] | |
TA-2005 | Drug Info | Phase 2 | Chronic obstructive pulmonary disease | [536223] | |
THRX-198321 | Drug Info | Phase 2 | Chronic obstructive pulmonary disease | [549872] | |
KUL-7211 | Drug Info | Phase 1 | Neurogenic bladder dysfunction | [547180] | |
L-796568 | Drug Info | Phase 1 | Obesity | [526432] | |
Meluadrine | Drug Info | Discontinued in Preregistration | Premature ejaculation | [545398] | |
Broxaterol | Drug Info | Discontinued in Phase 3 | Asthma | [544547] | |
Sibenadet | Drug Info | Discontinued in Phase 3 | Chronic obstructive pulmonary disease | [536661] | |
GSK-159797 | Drug Info | Discontinued in Phase 2 | Chronic obstructive pulmonary disease | [536223] | |
GSK159802 | Drug Info | Discontinued in Phase 2 | Chronic obstructive pulmonary disease; Asthma | [548082] | |
Milveterol | Drug Info | Discontinued in Phase 2 | Chronic obstructive pulmonary disease; Asthma | [537130] | |
Milveterol+Fluticasone | Drug Info | Discontinued in Phase 2 | Asthma; Chronic obstructive pulmonary disease | [550969] | |
PF-610355 | Drug Info | Discontinued in Phase 2 | Asthma; Chronic obstructive pulmonary disease | [548443] | |
Picumeterol | Drug Info | Discontinued in Phase 2 | Bronchodilator | [545347] | |
AR-C-89855 | Drug Info | Terminated | Chronic obstructive pulmonary disease | [547129] | |
L-755507 | Drug Info | Terminated | Discovery agent | [540554], [546489] | |
RP-58802B | Drug Info | Terminated | Asthma | [544951] | |
Inhibitor | (R,R)-(-)-fenoterol | Drug Info | [528842] | ||
(R,S)-(-)-fenoterol | Drug Info | [528842] | |||
(S,R)-(+)-fenoterol | Drug Info | [528842] | |||
1-(2-allylphenoxy)-3-morpholinopropan-2-ol | Drug Info | [530883] | |||
1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol | Drug Info | [530883] | |||
2-fluoronorepinehprine | Drug Info | [530478] | |||
CGP-12177A | Drug Info | [526033] | |||
DICHLOROISOPROTERENOL | Drug Info | [533801] | |||
GNF-PF-1694 | Drug Info | [529732] | |||
L-755507 | Drug Info | [526033] | |||
L-796568 | Drug Info | [530748] | |||
SDZ-201106 | Drug Info | [529732] | |||
Agonist | APD-209 | Drug Info | [544329] | ||
AR-C-89855 | Drug Info | [547130] | |||
Arformoterol | Drug Info | [535891], [537134] | |||
AZD-2115 | Drug Info | [532016] | |||
AZD-3199 | Drug Info | [544464] | |||
Bambuterol | Drug Info | [536563] | |||
Carmoterol | Drug Info | [537130] | |||
Clenbuterol | Drug Info | [535304], [536989] | |||
D 2343 | Drug Info | [537806] | |||
Fenoterol | Drug Info | [535311], [537192] | |||
Formoterol | Drug Info | [534986], [535115], [535518] | |||
GSK-159797 | Drug Info | [536223] | |||
GSK159802 | Drug Info | [550963] | |||
GSK642444 | Drug Info | [532150], [532651], [537130] | |||
GW642444 | Drug Info | [550963] | |||
Indacaterol | Drug Info | [536223], [537130] | |||
Isoprenaline | Drug Info | [538095] | |||
LAS 100977 | Drug Info | [531905] | |||
Milveterol | Drug Info | [550963] | |||
Milveterol+Fluticasone | Drug Info | [537130] | |||
MN-221 | Drug Info | [530213] | |||
Orciprenaline | Drug Info | [536544] | |||
PF-610355 | Drug Info | [531136] | |||
Picumeterol | Drug Info | [534374] | |||
Pirbuterol | Drug Info | [536347], [536442] | |||
Procaterol | Drug Info | [535606], [536454] | |||
PT005 | Drug Info | [551485] | |||
QVA-149 | Drug Info | [537130] | |||
R-salbutamol sulphate | Drug Info | [534530] | |||
Salbutamol | Drug Info | [535331] | |||
Salmeterol | Drug Info | [536966] | |||
TA-2005 | Drug Info | [536223] | |||
Terbutaline | Drug Info | [537680] | |||
Modulator | Broxaterol | Drug Info | [533154] | ||
BUCINDOLOL | Drug Info | ||||
GSK961081 | Drug Info | ||||
Isoetharine | Drug Info | [556264] | |||
Isoproterenol | Drug Info | [556264] | |||
KUL-7211 | Drug Info | [526702] | |||
Meluadrine | Drug Info | [526451] | |||
Metaproterenol Sulfate | Drug Info | [556264] | |||
Olodaterol | Drug Info | [533123] | |||
Ritodrine | Drug Info | [556264] | |||
RP-58802B | Drug Info | [526640] | |||
salbutamol dry-powder inhalation | Drug Info | ||||
Sibenadet | Drug Info | ||||
THRX-198321 | Drug Info | [531285] | |||
Vilanterol | Drug Info | [542374] | |||
Antagonist | Butoxamine | Drug Info | [535096] | ||
ICI 118,551 | Drug Info | [537716] | |||
Levalbuterol | Drug Info | [537409] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Calcium signaling pathway | ||||
cGMP-PKG signaling pathway | |||||
cAMP signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Endocytosis | |||||
Adrenergic signaling in cardiomyocytes | |||||
Salivary secretion | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Beta2 adrenergic receptor signaling pathway | |||||
Pathway Interaction Database | Arf6 trafficking events | ||||
Arf6 signaling events | |||||
Reactome | Adrenoceptors | ||||
G alpha (s) signalling events | |||||
WikiPathways | Monoamine GPCRs | ||||
Calcium Regulation in the Cardiac Cell | |||||
GPCRs, Class A Rhodopsin-like | |||||
Vitamin D Receptor Pathway | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
GPCRs, Other | |||||
References | |||||
Ref 522239 | ClinicalTrials.gov (NCT00625521) Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions. U.S. National Institutes of Health. | ||||
Ref 522325 | ClinicalTrials.gov (NCT00683449) Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma. U.S. National Institutes of Health. | ||||
Ref 522407 | ClinicalTrials.gov (NCT00736489) Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199. U.S. National Institutes of Health. | ||||
Ref 524423 | ClinicalTrials.gov (NCT01936649) Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.. U.S. National Institutes of Health. | ||||
Ref 524493 | ClinicalTrials.gov (NCT01970501) Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure. U.S. National Institutes of Health. | ||||
Ref 524508 | ClinicalTrials.gov (NCT01977443) Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC). U.S. National Institutes of Health. | ||||
Ref 524708 | ClinicalTrials.gov (NCT02109406) Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD. U.S. National Institutes of Health. | ||||
Ref 525067 | ClinicalTrials.gov (NCT02343458) Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD. U.S. National Institutes of Health. | ||||
Ref 526432 | Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr. 2002 Oct;76(4):780-8. | ||||
Ref 532150 | Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. PulmPharmacol Ther. 2013 Apr;26(2):256-64. | ||||
Ref 536223 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 536500 | Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77. | ||||
Ref 536535 | Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. Respir Med. 2008 Mar;102(3):449-56. Epub 2007 Nov 19. | ||||
Ref 536567 | Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation. J Med Toxicol. 2007 Jun;3(2):56-60. | ||||
Ref 536661 | Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17. Epub 2008 Mar 18. | ||||
Ref 537130 | Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. | ||||
Ref 538236 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071438. | ||||
Ref 538303 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075877. | ||||
Ref 538350 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 083346. | ||||
Ref 538363 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 086711. | ||||
Ref 540402 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3464). | ||||
Ref 540403 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3465). | ||||
Ref 540554 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3931). | ||||
Ref 540946 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 557). | ||||
Ref 540951 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 558). | ||||
Ref 540957 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 559). | ||||
Ref 540968 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 560). | ||||
Ref 541721 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6601). | ||||
Ref 542219 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7205). | ||||
Ref 542268 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7250). | ||||
Ref 542292 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7272). | ||||
Ref 542314 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7294). | ||||
Ref 542374 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353). | ||||
Ref 542479 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7455). | ||||
Ref 542501 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7479). | ||||
Ref 542545 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7543). | ||||
Ref 542572 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7582). | ||||
Ref 544547 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000105) | ||||
Ref 544951 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001694) | ||||
Ref 545347 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002942) | ||||
Ref 545398 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003111) | ||||
Ref 545941 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005434) | ||||
Ref 546489 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008526) | ||||
Ref 547129 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013263) | ||||
Ref 547180 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013676) | ||||
Ref 548082 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021784) | ||||
Ref 548296 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024247) | ||||
Ref 548443 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025582) | ||||
Ref 548577 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026746) | ||||
Ref 526033 | J Med Chem. 2001 Apr 26;44(9):1456-66.(4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. | ||||
Ref 526451 | Effects of meluadrine tartrate and ritodrine hydrochloride on oxytocin-induced uterine contraction, uterine arterial blood flow and maternal cardiovascular function in pregnant goats. Jpn J Pharmacol. 2002 Oct;90(2):107-13. | ||||
Ref 526640 | RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. Pulm Pharmacol. 1992 Sep;5(3):203-12. | ||||
Ref 526702 | Pharmacological profile of KUL-7211, a selective beta-adrenoceptor agonist, in isolated ureteral smooth muscle. J Pharmacol Sci. 2003 Aug;92(4):411-9. | ||||
Ref 528842 | J Med Chem. 2007 Jun 14;50(12):2903-15. Epub 2007 May 17.Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. | ||||
Ref 529732 | Bioorg Med Chem Lett. 2008 Oct 15;18(20):5391-5. Epub 2008 Sep 14.Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. | ||||
Ref 530213 | Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant. J Obstet Gynaecol Res. 2009 Jun;35(3):405-13. | ||||
Ref 530478 | Bioorg Med Chem. 2009 Dec 1;17(23):7987-92. Epub 2009 Oct 13.Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines. | ||||
Ref 530748 | Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9. Epub 2010 Feb 4.Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles. | ||||
Ref 530883 | Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404. Epub 2010 Apr 9.A vHTS approach for the identification of beta-adrenoceptor ligands. | ||||
Ref 531136 | Inhalation by design: novel ultra-long-acting beta(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem. 2010 Sep 23;53(18):6640-52. | ||||
Ref 531285 | THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol. 2011 Mar;79(3):389-99. | ||||
Ref 531905 | Pharmacological characterization of abediterol, a novel inhaled beta(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. J Pharmacol Exp Ther. 2012 Aug;342(2):497-509. | ||||
Ref 532016 | Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115. Expert Opin Ther Pat. 2012 Nov;22(11):1377-83. | ||||
Ref 532150 | Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. PulmPharmacol Ther. 2013 Apr;26(2):256-64. | ||||
Ref 533154 | Broxaterol, a new beta 2-adrenoceptor agonist compared to salbutamol in asthmatics, oral and inhalation treatment. Respiration. 1989;55 Suppl 2:15-9. | ||||
Ref 533801 | J Med Chem. 1994 May 13;37(10):1518-25.The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic beta-adrenergic receptor antagonists. | ||||
Ref 534374 | Picumeterol: dissociation of improvement in lung function and reduction of airways hyperresponsiveness in asthmatics. Br J Clin Pharmacol. 1997 Feb;43(2):169-76. | ||||
Ref 534530 | Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax. 1997 Oct;52(10):849-52. | ||||
Ref 534986 | Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2000;(2):CD001104. | ||||
Ref 535096 | Partial agonistic effects of carteolol on atypical beta-adrenoceptors in the guinea pig gastric fundus. Jpn J Pharmacol. 2000 Nov;84(3):287-92. | ||||
Ref 535115 | Tocolytic effects of a long-acting beta2-adrenoceptor agonist, formoterol, in rats. J Pharm Pharmacol. 2000 Nov;52(11):1417-23. | ||||
Ref 535304 | Beta(2)-adrenoceptor stimulation enhances latent transforming growth factor-beta-binding protein-1 and transforming growth factor-beta1 expression in rat hippocampus after transient forebrain ischemia. Neuroscience. 2001;107(4):593-602. | ||||
Ref 535311 | Effect of fenoterol-induced constitutive beta(2)-adrenoceptor activity on contractile receptor function in airway smooth muscle. Eur J Pharmacol. 2001 Nov 23;431(3):353-9. | ||||
Ref 535331 | Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8. | ||||
Ref 535518 | Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104. | ||||
Ref 535606 | beta 2-adrenoceptor polymorphism and effect of inhaled beta 2-stimulant (procaterol) on airway resistance measured by body plethysmography in healthy volunteers. Nihon Kokyuki Gakkai Zasshi. 2002 Aug;40(8):637-43. | ||||
Ref 535891 | Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Drugs R D. 2004;5(1):25-7. | ||||
Ref 536223 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | ||||
Ref 536347 | A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene. 2007 May 31;26(26):3777-88. Epub 2007 Jan 29. | ||||
Ref 536454 | Inhalation and incubation with procaterol increases diaphragm muscle contractility in mice. Allergol Int. 2007 Sep;56(3):285-91. Epub 2007 Aug 1. | ||||
Ref 536544 | Male--female differences in the impact of beta-adrenoceptor stimulation on resistance to experimental metastasis: exploring the effects of age and gonadal hormone involvement. J Neuroimmunol. 2008 Jan;193(1-2):113-9. Epub 2007 Nov 26. | ||||
Ref 536563 | Enantiomeric separation of beta2-agonists on macrocyclic antibiotic chiral stationary phases in high performance liquid chromatography. Pharmazie. 2007 Nov;62(11):836-40. | ||||
Ref 536989 | Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7. | ||||
Ref 537130 | Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. | ||||
Ref 537134 | Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9. | ||||
Ref 537192 | Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75. | ||||
Ref 537409 | Beta-blockers in the treatment of hypertension: are there clinically relevant differences? Postgrad Med. 2009 May;121(3):90-8. | ||||
Ref 537680 | Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline. Pharmacology. 1975;13(3):201-11. | ||||
Ref 537716 | Selective beta 2-adrenoceptor antagonists: derivatives of ICI 118,551 and a binary aryloxypropanolamine. J Pharm Pharmacol. 1988 Nov;40(11):803-5. | ||||
Ref 537806 | A new beta 2-adrenoceptor agonist--D 2343--with long duration. Inhalation comparison with terbutaline in asthmatics. Allergy. 1984 Aug;39(6):485-9. | ||||
Ref 538095 | Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. | ||||
Ref 542374 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353). | ||||
Ref 544329 | Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Retraction in: Drug Des Devel Ther. 2013; 7: 1385. | ||||
Ref 544464 | Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting beta2-adrenoreceptor agonist (uLABA). Drug Des Devel Ther. 2015; 9: 753-762. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.